Market Research Logo

Malaysia Pharmaceuticals & Healthcare Q4 2018

Malaysia Pharmaceuticals & Healthcare Q4 2018

Key View:

The Malaysian pharmaceutical market will benefit from a higher expenditure on healthcare, with the governmentannouncing that it aims to increase its annual budget allocation to the healthcare sector as part of its ongoing effort to improve thehealth and well-being of the population. Furthermore, we expect the removal of the 6% goods and service tax (GST) will reduce theprice of medicines not previously included on the zero-rating list, providing a short-term boost to drug spending in Malaysia.Concerns over the high prices of pharmaceuticals will remain a key theme in Malaysia in the long-term. As such, the Malaysiangovernment will continue to intervene and establish pharmaceutical price controls to increase the population's access to affordablemedicines.


Key View
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Healthcare Market Forecast
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Industry Risk/Reward Index
Asia Pacific Innovative Pharmaceuticals & Healthcare Risk/Reward Index
Innovative Pharmaceuticals Risk/Reward Index
Regulatory Development
Regulatory Review
Market Overview
Competitive Landscape
Company Profile
Chemical Company Of Malaysia
Kotra Pharma
Novartis
Ranbaxy Malaysia
Sanofi
Malaysia Demographic Outlook
Pharmaceuticals & Healthcare Glossary
Pharmaceuticals & Healthcare Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report